Business Description
Capricor Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US14070B1017
Description
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.66 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.39 | |||||
| Beneish M-Score | 6.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 260.9 | |||||
| 3-Year EBITDA Growth Rate | 0.4 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -14.9 | |||||
| 3-Year Book Growth Rate | -19.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.65 | |||||
| 9-Day RSI | 37.41 | |||||
| 14-Day RSI | 40.81 | |||||
| 6-1 Month Momentum % | 120.77 | |||||
| 12-1 Month Momentum % | 58.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.63 | |||||
| Quick Ratio | 1.63 | |||||
| Cash Ratio | 1.26 | |||||
| Days Sales Outstanding | 36.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.8 | |||||
| Shareholder Yield % | 0.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -95.63 | |||||
| Net Margin % | -88.52 | |||||
| FCF Margin % | -109.65 | |||||
| ROE % | -268.3 | |||||
| ROA % | -45.33 | |||||
| ROIC % | -71.4 | |||||
| ROC (Joel Greenblatt) % | -336.99 | |||||
| ROCE % | -140.34 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.96 | |||||
| PB Ratio | 7.45 | |||||
| Price-to-Tangible-Book | 7.36 | |||||
| EV-to-EBIT | -5.53 | |||||
| EV-to-Forward-EBIT | -4.47 | |||||
| EV-to-EBITDA | -5.79 | |||||
| EV-to-Forward-EBITDA | -4.47 | |||||
| EV-to-Revenue | 5.29 | |||||
| EV-to-Forward-Revenue | 9.38 | |||||
| EV-to-FCF | -4.82 | |||||
| Price-to-Net-Current-Asset-Value | 11.49 | |||||
| Price-to-Net-Cash | 47.1 | |||||
| Earnings Yield (Greenblatt) % | -18.08 | |||||
| FCF Yield % | -16.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Capricor Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 23.286 | ||
| EPS (TTM) (€) | -0.774 | ||
| Beta | 0.64 | ||
| Volatility % | 113.47 | ||
| 14-Day RSI | 40.81 | ||
| 14-Day ATR (€) | 0.243222 | ||
| 20-Day SMA (€) | 5.396 | ||
| 12-1 Month Momentum % | 58.56 | ||
| 52-Week Range (€) | 2.5 - 7.13 | ||
| Shares Outstanding (Mil) | 31.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Capricor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Capricor Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Capricor Therapeutics Inc Frequently Asked Questions
What is Capricor Therapeutics Inc(FRA:4LN2)'s stock price today?
The current price of FRA:4LN2 is €4.71. The 52 week high of FRA:4LN2 is €7.13 and 52 week low is €2.50.
When is next earnings date of Capricor Therapeutics Inc(FRA:4LN2)?
The next earnings date of Capricor Therapeutics Inc(FRA:4LN2) is 2024-05-10 Est..
Does Capricor Therapeutics Inc(FRA:4LN2) pay dividends? If so, how much?
Capricor Therapeutics Inc(FRA:4LN2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers